Candel Therapeutics Q4 operating loss misses analyst expectations

Reuters03-12
Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 operating loss misses analyst expectations

Overview

  • US cancer immunotherapy developer's Q4 operating loss missed analyst expectations

  • Q4 net loss widened to $29.5 mln from $14.1 mln a year earlier

  • Company bolstered cash position with $130 mln loan and $100 mln equity offering

Outlook

  • Company plans to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026

  • Candel expects to submit BLA for aglatimagene in prostate cancer in Q4 2026

  • Company says cash position is sufficient to fund operations into Q1 2028

Result Drivers

  • R&D EXPENSES - Higher research and development costs driven by increased manufacturing, clinical trial and regulatory activities, and employee-related expenses

  • COMMERCIAL READINESS SPEND - General and administrative expenses rose due to commercial readiness costs, employee-related expenses, and higher professional and consulting fees

Company press release: ID:nGNX3t8psT

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

-$29.50 mln

Q4 Income From Operations

Miss

-$15.75 mln

-$13.93 mln (6 Analysts)

Q4 Basic EPS

-$0.54

Q4 Operating Expenses

$15.75 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Candel Therapeutics Inc is $16.00, about 213.7% above its March 11 closing price of $5.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment